Bayesian meta-analysis of studies with rare events: Do the choice of prior distributions and the exclusion of studies without events in both arms matter?

Institute of social and preventive medicine, University of Bern, Basel, Schweiz
Institute for clinical epidemiology and biostatistics, University of Basel, Basel, Schweiz
Applied health research center (AHRC), department of medicine, University of Toronto, Toronto, Canada
London School of Hygiene and Tropical Medicine (LSHTM), University of London, London, United Kingdom
DOI
10.7287/peerj.preprints.27732v1
Subject Areas
Clinical Trials, Epidemiology, Public Health, Statistics
Keywords
rare events, fixed effect, Bayesian approach, random effects
Copyright
© 2019 Aghlmandi et al.
Licence
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ Preprints) and either DOI or URL of the article must be cited.
Cite this article
Aghlmandi S, Jüni P, Carpenter J, Zwahlen M. 2019. Bayesian meta-analysis of studies with rare events: Do the choice of prior distributions and the exclusion of studies without events in both arms matter? PeerJ Preprints 7:e27732v1

Abstract

Randomized controlled trials (RCTs) analyzing serious adverse events often observe low incidence and might even observe zero events in either or both of the treatment and control arms. In the meta-analysis of RCTs of adverse events, it is unclear whether trials with zero events in both arms provide any information for the summary risk ratio (RR) or odds ratio (OR). Studies with zero events in both arms are usually excluded in both frequentist and Bayesian meta-analysis. We used a fully probabilistic approach—a Bayesian framework—for the meta-analysis of studies with rare events, and systematically assessed whether exclusion of studies with no events in both arms produced different results compared to keeping all studies in the meta-analysis. We did this by conducting a simulation study in which we assessed the bias in the point estimate of the log(OR) and the coverage of the 95% posterior interval for the log(OR) for different analytical decisions and choices in fixed effect and random effects meta-analysis. We used simulated data generated from a known fixed effect or random effects data scenario (each scenario with a 1000 meta-analysis data-set). We found that the uniform and Jeffrey’s prior on the baseline risk in the control group leads to biased results and a reduced coverage, and that setting the prior distribution on the log(odds) scale worked better. We also found nearly identical results regardless of whether studies with no events in both arms were excluded or not.

Author Comment

This work is focusing on the open issue of how to meta-analyse studies (RCTs) with rare outcomes. We have done a simulation study and used fully probabilistic approach and compared it with already existing frequentist approches.

Supplemental Information

Tables included in the manuscript

DOI: 10.7287/peerj.preprints.27732v1/supp-1

Figure 1

Coverage probability of 95% CIs and bias for log(OR) = 0 and log(OR)=0.69 estimate for FE method when trials with no events in both arms were included (bold icons in the graph are scenarios with more than 30% in both arms)

DOI: 10.7287/peerj.preprints.27732v1/supp-2

Figure 2

Coverage probability of 95% CIs and bias for log(OR) estimate for RE method with half-normal(mean= 0.5) prior for statistical heterogeneity and different scenarios of log(OR)

DOI: 10.7287/peerj.preprints.27732v1/supp-3

Figure 3

Coverage probability of 95% CIs and bias for log(OR) estimate for RE method with half-normal(mean= 0.5) prior for statistical heterogeneity for different scenarios of log(OR)

DOI: 10.7287/peerj.preprints.27732v1/supp-4

Figure 4

Forest plot of an MA of Rosiglitazone for MI

DOI: 10.7287/peerj.preprints.27732v1/supp-5

Figure 5

Forrest plot of an MA of Rosiglitazone for CV death

DOI: 10.7287/peerj.preprints.27732v1/supp-6

Supplemental II

JAGS codes for the study

DOI: 10.7287/peerj.preprints.27732v1/supp-7

Supplemental III

R codes for the study

DOI: 10.7287/peerj.preprints.27732v1/supp-8

Supplemental I

Tables and figures for as a supplemental

DOI: 10.7287/peerj.preprints.27732v1/supp-9

Figure S1

Coverage probability of 95% CIs and bias

DOI: 10.7287/peerj.preprints.27732v1/supp-10

Figure S2

Coverage probability of 95% CIs and bias

DOI: 10.7287/peerj.preprints.27732v1/supp-11

Figure S3

Coverage probability of 95% CIs and bias

DOI: 10.7287/peerj.preprints.27732v1/supp-12

Figure S4

Coverage probability of 95% CIs and bias

DOI: 10.7287/peerj.preprints.27732v1/supp-13

Figure S5

Coverage probability of 95% CIs and bias

DOI: 10.7287/peerj.preprints.27732v1/supp-14

Figure S6

Coverage probability of 95% CIs and bias

DOI: 10.7287/peerj.preprints.27732v1/supp-15